According to a literature survey, The prevalence of Blepharitis may vary from 37.0% to 50.0?cording to some reports in the literature, most often affecting females over 50 years of age. Females accounted for 55% to 60% of cases, and males for 40% to 45%. Regarding the severity of the disease, more than half were diagnosed with mild blepharitis 55% to 57.8%), 40% to 42.6?ses were diagnosed with moderate, and 1.6% to 3.5% as severe.
Comprehensive insight on patient segmentation based on age, sex, Types (anterior blepharitis & posterior blepharitis), the severity of infection (Acute & Chronic), Risk factors (Dry eye, Dermatologic conditions, Demodicosis, Rosacea, Isotretinoin, Giant papillary conjunctivitis & Others), Stages (mild, moderate & Severe) Signs & Symptoms, Clinical Manifestations, Treatment types (Antibiotics; Topical and systemic, anti-inflammatory agents and Others) has been provided into the epidemiology section of the Blepharitis and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Bausch & Lomb Incorporated, Tarsus Pharmaceuticals, Inc., Keyrus Biopharma, Nicox Ophthalmics, Inc., Sun Pharma Global FZE, AxeroVision, Inc., Merck Sharp & Dohme Corp., Alcon Research, Tissue Tech Inc., Galderma, Kala Pharmaceuticals, Inc., NovaBay Pharmaceuticals, Inc., TearScience, Inc.,
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,